+ BCB + SMK
Pembimbing:
dr. I Putu Ardhika Y, Sp.A
LAPORAN KASUS
• Nama : By Nurdiansyah
• Umur : 15 hari
• Jenis Kelamin : laki-laki
• Alamat : Bajuin, Pelaihari.
• TL/JL/CL : 08-02-2019/ Spt Bk/ Bidan
• BBL/PBL : 3100 gram / 51 cm
• BBS : 3800 gram
• No RM : 27 99 28
• Tgl MRS : 23 February 2019
• Tgl KRS : 28 February 2019
2
Kasus
Anamnesis
• Muncul bintik-bintik kemerahan dukulit dengan berbagai ukuran, awalnya 2 hari Smrs,
pertama muncul di area wajah, kemudian ke sekitar paha dan seluruh tubuh menyebar. Bintik-
bitnik semakin membesar berisi cairan dan pecah, menyisakan keropeng kekuningan di
permukaan kulit dan kulit tampak kering dan pecah-pecah.
• Demam di sangkal, berobat kebidan diberi Amoxycilin syrup , namun tidak membaik.
• Minum ASI (+) banyak.
• Riw Hygine buruk, bayi dimandikan 1x sehari.
• Riw Kehamilan dan persalinan : Bayi Cukup bulan, persalinan normal ditolong bidan, bayi
langsung menangis, lahir dengan berat badan lahir cukup dan sesuai masa kehamilan,.
3
Kasus
Pemeriksaan Fisik
Keadaan umum/ Kesadaran : Baik / Gerak aktif
Tanda Vital :
Denyut jantung : 134 x/menit, kuat angkat reguler
Temperatur : 36,7 0C
Respirasi : 30 x/menit, reguler
CRT : < 2 detik
4
• ikterik (-) , sianosis (-), Multiple Makula eritema, dengan Kasus
Kulit squama dan crusta kuning tua seperti madu kering
Kepala • mesosefali, kaput suksadeneum (-), lessi kulit (+)
Mulut • mukosa bibir basah, sianosis (-), sariawan (-) gusi berdarah(-)
5
Kasus
Abdomen • cembung, H/L/M tidak teraba, perkusi timpani
6
Clinical Picture
Pemeriksaan Hasil Nilai Rujukan Satuan Kasus
HEMATOLOGI
Hemoglobin 12.8 14.00-24.00 g/dl
Leukosit 7.6 4.65-10-3 ribu/ul
Eritrosit 4.03 4.80-7.10 juta/ul
Hematokrit 38.2 44.00-64.00 vol%
Trombosit 368 150-356 ribu/ul
RDW-CV 14.7 12.1-14.0 %
Pemeriksaan Penunjang
MCV, MCH, MCHC
MCV 94.8 75.0-96.0 fl
Hasil Lab
MCH 31.7
33.5
28.0-32.0 pg (08/02/2019)
MCHC 33.0-37.0 %
HITUNG JENIS
Gran% 17.9 50.0-70.0 %
Limfosit% 74.5 25.0-40.0 %
MID% 7.6 4.0-11.0 %
Gran# 1.4 2.50-7.00 ribu/ul
Limfosit# 5.7 1.25-4.0 ribu/ul
MID# 0.5 ribu/ul
8
Kasus
Diagnosis Kerja
• I. Impetigo Bulosa
• II. Bayi Berat Lahir Cukup
• III. Bayi Cukup Bulan
• IV. Sesuai Masa Kehamilan
9
Kasus
Penatalaksanaan
I. Rawat Box
II. O2 (-)
III. ASI on demand
IV. Inf D5 ¼ NS 6 tpm micro drip
Inj. Cefotaxim 2 x 160 mg iv
V. Beri zalf Gentamisin 2x sehari tipis-tipis dipermukaan lesi
VI. Bersihkan dan kompres lesi dengan NaCl 0.9% 2 x sehari
VII. Monitor : Keadaan umum, tanda vital.
10
Berat lahir pasien adalah Bayi Berat Lahir Cukup Diskusi Kasus
3100 gr (BBLC)
TEORI
1. BBLL (bayi berat lahir lebih) : bayi yang dilahirkan dengan berat lahir lebih
dari 4000 gram
2. BBLC (bayi berat lahir cukup) : bayi yang dilahirkan dengan berat lahir
antara 2500 gram dan 4000 gram
3. BBLR (bayi berat lahir rendah) : bayi yang dilahirkan dengan berat lahir
antara 1500gr dan 2500gr tanpa memandang usia gestasi
4. BBLSR (bayi berat lahir sangat rendah) : bayi yang dilahirkan dengan berat
lahir antara 1000 gram dan 1500 gram
5. BBLSAR (bayi berat lahir sangat amat rendah) : bayi yang dilahirkan
dengan berat lahir kurang dari 1000 gram.
11
Diskusi Kasus
Pasien lahir dalam usia kehamilan 38-
39 minggu Bayi Cukup Bulan (BCB)
TEORI
1. Bayi Kurang Bulan (BKB) : Bayi dilahirkan dengan masa gestasi <37
minggu (<259hari)
2.Bayi Cukup Bulan (BCB) : Bayi dilahirkan dengan masa gestasi
antara 37 - 42 minggu (259-293 hari)
3. Bayi Lebih Bulan (BLB) : Bayi dilahirkan dengan masa gestasi > 42
minggu (294 hari)
12
Grafik Lubchenco
Diskusi Kasus
13
Impetigo
• Acute, highly contagious gram-positive bacterial
infection of the superficial layers of the epidermis. Skin
lesions such as cuts, abrasions, and chickenpox can also
become secondarily infected (impetiginized) with the
same pathogens that produce classic impetigo.
• Most commonly in children, especially those who live in
hot, humid climates.
• Impetigo occurs in 2 forms: bullous and nonbullous
• Nonbullous impetigo is the more common form,
constituting approximately 70% of impetigo cases. It
tends to affect skin on the face or extremities that has
been disrupted by bites, cuts, abrasions, other trauma,
or diseases such as varicella.
Etiology
Nonbullous impetigo Bullous impetigo
Nonbullous impetigo
Treatment
• Topical Antibiotic Treatment • Case :
• Topical antibiotic therapy is considered the treatment of • Used Gentamicin Skin Ointment
choice for individuals with uncomplicated localized
impetigo. Topical therapy eradicates isolated disease and • Removal of the infected crusts
limits the individual-to-individual spread. The topical and debris with Nacl 0.9%, soap
agent is applied after removal of the infected crusts and and water
debris with soap and water. Disadvantages of topical
treatment are that it cannot eradicate organisms from the
respiratory tract and that applying topical medications to
extensive lesions is difficult.
• Mupirocin ointment (Bactroban).
• Retapamulin (Altabax) ointment.
• Topical sodium fusidate (fusidic acid).
• Clindamycin (cream, lotion, and foam) is useful in several
MRSA.
• Gentamicin ointment or cream.
• Systemic Antibiotic Treatment
• Infections that are widespread, complicated, or are • Case :
associated with systemic manifestations (outbreaks of
poststreptococcal glomerulonephritis) are usually treated • Inj Cefotaxim (cephalosporins)
with antibiotics that have gram-positive bacterial 2x 160 mg/ iv
coverage. Systemic therapy is also recommended if
multiple incidents of pyoderma occur within daycare,
family, or athletic team settings.
• Beta-lactamase‒resistant antibiotics (eg, cephalosporins,
amoxicillin-clavulanate, dicloxacillin) are recommended
as S aureus isolates from impetigo are usually methicillin-
susceptible. [37] Cephalexin appears to be the drug of
choice for oral antimicrobial therapy in children.
• Erythromycin and clindamycin are alternatives in patients
with penicillin hypersensitivity. Macrolide resistance has
been increasing in the United States. Thus, avoid
treatment of impetigo with erythromycin in geographic
regions that are known to have a high resistance rate.
Group A beta hemolytic streptococci (GABHS) and S
aureus resistance to clindamycin has also been reported.
Post Treatment
21